Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation

[1] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, N Engl J Med, 333, pp. 1581-1587, (1995)

[2] Hacke W., Kaste M., Fieschi C., Et al., Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS), JAMA, 274, pp. 1017-1025, (1995)

[3] Hacke W., Kaste M., Fieschi C., Et al., Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators, Lancet, 352, pp. 1245-1251, (1998)

[4] Hacke W., Kaste M., Bluhmki E., Et al., Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke, N Engl J Med, 359, pp. 1317-1329, (2008)

[5] Lansberg M.G., Thijs V.N., Bammer R., Et al., Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke, Stroke, 38, pp. 2275-2278, (2007)

[6] Tanne D., Kasner S.E., Demchuk A.M., Et al., Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey, Circulation, 105, pp. 1679-1685, (2002)

[7] Adams H., Adams R., Del Zoppo G., Goldstein L.B., Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association, Stroke, 36, pp. 916-923, (2005)

[8] Kim Y.D., Lee J.H., Jung Y.H., Et al., Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use, J Neurol Sci, 298, pp. 101-105, (2010)

[9] Meretoja A., Putaala J., Tatlisumak T., Et al., Off-label thrombolysis is not associated with poor outcome in patients with stroke, Stroke, 41, pp. 1450-1458, (2010)

[10] Prabhakaran S., Rivolta J., Vieira J.R., Et al., Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke, Arch Neurol, 67, pp. 559-563, (2010)

[1] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, N Engl J Med, 333, pp. 1581-1587, (1995)

[2] Hacke W., Kaste M., Fieschi C., Et al., Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS), JAMA, 274, pp. 1017-1025, (1995)

[3] Hacke W., Kaste M., Fieschi C., Et al., Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators, Lancet, 352, pp. 1245-1251, (1998)

[4] Hacke W., Kaste M., Bluhmki E., Et al., Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke, N Engl J Med, 359, pp. 1317-1329, (2008)

[5] Lansberg M.G., Thijs V.N., Bammer R., Et al., Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke, Stroke, 38, pp. 2275-2278, (2007)

[6] Tanne D., Kasner S.E., Demchuk A.M., Et al., Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey, Circulation, 105, pp. 1679-1685, (2002)

[7] Adams H., Adams R., Del Zoppo G., Goldstein L.B., Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association, Stroke, 36, pp. 916-923, (2005)

[8] Kim Y.D., Lee J.H., Jung Y.H., Et al., Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use, J Neurol Sci, 298, pp. 101-105, (2010)

[9] Meretoja A., Putaala J., Tatlisumak T., Et al., Off-label thrombolysis is not associated with poor outcome in patients with stroke, Stroke, 41, pp. 1450-1458, (2010)

[10] Prabhakaran S., Rivolta J., Vieira J.R., Et al., Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke, Arch Neurol, 67, pp. 559-563, (2010)